New drug aims to tame dangerous blood vessel inflammation

NCT ID NCT04930094

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested if an injectable drug called secukinumab could help control giant cell arteritis, a serious inflammatory disease of blood vessels. It involved 355 patients and compared the drug against a placebo, with both groups also taking a tapering course of steroids. The main goal was to see if the drug could help patients achieve and maintain remission while allowing them to use lower doses of steroids for a shorter time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Advanced Rheumatology of Houston

Spring, Texas, 77382, United States
Cedars Sinai Medical Center

Los Angeles, California, 90048, United States
IRIS Research and Development

Plantation, Florida, 33324, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Novartis Investigative Site

Iowa City, Iowa, 52242, United States
Novartis Investigative Site

La Plata, Buenos Aires, B1900AWT, Argentina
Novartis Investigative Site

Capital Federal, C1023AAB, Argentina
Novartis Investigative Site

Parramatta, New South Wales, 2150, Australia
Novartis Investigative Site

Southport, Queensland, 4215, Australia
Novartis Investigative Site

Hobart, Tasmania, 7000, Australia
Novartis Investigative Site

Heidelberg Heights, Victoria, 3081, Australia
Novartis Investigative Site

Malvern East, Victoria, 3145, Australia
Novartis Investigative Site

Murdoch, Western Australia, 6150, Australia
Novartis Investigative Site

Liverpool, 2170, Australia
Novartis Investigative Site

Innsbruck, Tyrol, 6020, Austria
Novartis Investigative Site

Graz, 8036, Austria
Novartis Investigative Site

Leuven, 3000, Belgium
Novartis Investigative Site

Liège, 4000, Belgium
Novartis Investigative Site

Juiz de Fora, Minas Gerais, 36010 570, Brazil
Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, 90035-003, Brazil
Novartis Investigative Site

Sao Jose Rio Preto, São Paulo, 15090 000, Brazil
Novartis Investigative Site

Plovdiv, 4000, Bulgaria
Novartis Investigative Site

Plovdiv, 4002, Bulgaria
Novartis Investigative Site

Montreal, Quebec, H1T 2M4, Canada
Novartis Investigative Site

Sherbrooke, Quebec, J1G 2E8, Canada
Novartis Investigative Site

Trois-Rivières, Quebec, G9A 3X2, Canada
Novartis Investigative Site

Brno, 625 00, Czechia
Novartis Investigative Site

Prague, 128 00, Czechia
Novartis Investigative Site

Prague, 148 00, Czechia
Novartis Investigative Site

Uherské Hradiště, 686 01, Czechia
Novartis Investigative Site

Aarhus N, 8200, Denmark
Novartis Investigative Site

Esbjerg, 6700, Denmark
Novartis Investigative Site

Vejle, DK-7100, Denmark
Novartis Investigative Site

Tallinn, 10138, Estonia
Novartis Investigative Site

Tartu, 50708, Estonia
Novartis Investigative Site

Helsinki, 00290, Finland
Novartis Investigative Site

Kuopio, 70100, Finland
Novartis Investigative Site

Lahti, 15850, Finland
Novartis Investigative Site

Turku, 20520, Finland
Novartis Investigative Site

Brest, 29200, France
Novartis Investigative Site

Dijon, 21000, France
Novartis Investigative Site

Le Mans, 72000, France
Novartis Investigative Site

Lille, 59037, France
Novartis Investigative Site

Marseille, 13008, France
Novartis Investigative Site

Nantes, 44093, France
Novartis Investigative Site

Paris, 75013, France
Novartis Investigative Site

Paris, 75014, France
Novartis Investigative Site

Strasbourg, 67000, France
Novartis Investigative Site

Toulouse, 31059, France
Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Novartis Investigative Site

Würzburg, Bavaria, 97080, Germany
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Berlin, 13125, Germany
Novartis Investigative Site

Bonn, 53105, Germany
Novartis Investigative Site

Dresden, 01067, Germany
Novartis Investigative Site

Erlangen, 91054, Germany
Novartis Investigative Site

Herne, 44649, Germany
Novartis Investigative Site

Ludwigshafen, 67063, Germany
Novartis Investigative Site

Athens, 115 27, Greece
Novartis Investigative Site

Guatemala City, 01010, Guatemala
Novartis Investigative Site

Pécs, Baranya, 7623, Hungary
Novartis Investigative Site

Debrecen, Hajdu Bihar Megye, 4032, Hungary
Novartis Investigative Site

Budapest, H-1083, Hungary
Novartis Investigative Site

Szeged, 6725, Hungary
Novartis Investigative Site

Tel Aviv, 6423906, Israel
Novartis Investigative Site

Brescia, BS, 25123, Italy
Novartis Investigative Site

Cona, FE, 44124, Italy
Novartis Investigative Site

Florence, FI, 50134, Italy
Novartis Investigative Site

Milan, MI, 20132, Italy
Novartis Investigative Site

Siena, SI, 53100, Italy
Novartis Investigative Site

Gjettum, 1346, Norway
Novartis Investigative Site

Moss, 1538, Norway
Novartis Investigative Site

Bydgoszcz, 85-168, Poland
Novartis Investigative Site

Krakow, 30-002, Poland
Novartis Investigative Site

Lisbon, 1649-035, Portugal
Novartis Investigative Site

Ponte de Lima, 4990-041, Portugal
Novartis Investigative Site

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site

Badalona, Barcelona, 08916, Spain
Novartis Investigative Site

Sabadell, Barcelona, 08208, Spain
Novartis Investigative Site

Bilbao, Bizkaia, 48013, Spain
Novartis Investigative Site

Santander, Cantabria, 39008, Spain
Novartis Investigative Site

Pamplona, Navarre, 31008, Spain
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Barcelona, 08041, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28046, Spain
Novartis Investigative Site

Valencia, 46026, Spain
Novartis Investigative Site

Malmo, 221 85, Sweden
Novartis Investigative Site

Basel, 4031, Switzerland
Novartis Investigative Site

Geneva, 1211, Switzerland
Novartis Investigative Site

Sankt Gallen, 9007, Switzerland
Novartis Investigative Site

Zurich, 8091, Switzerland
Novartis Investigative Site

Istanbul, Fatih, 34098, Turkey (Türkiye)
Novartis Investigative Site

Istanbul, Pendik, 34899, Turkey (Türkiye)
Novartis Investigative Site

Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)
Novartis Investigative Site

Edinburgh, Scotland, EH4 2XU, United Kingdom
Novartis Investigative Site

Stoke-on-Trent, Staffordshire, ST6 7AG, United Kingdom
Novartis Investigative Site

Newcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom
Novartis Investigative Site

Dundee, DD1 9SY, United Kingdom
Osteoporosis and Clinical Trial Ctr

Hagerstown, Maryland, 21740, United States
Precision Comp Clin Research

Grapevine, Texas, 76051, United States
Sarasota Arthritis Res Ctr

Sarasota, Florida, 34239, United States
University Of Iowa

Iowa City, Iowa, 52242, United States
West Tennessee Research Institute

Jackson, Tennessee, 38305, United States

Conditions

Explore the condition pages connected to this study.

GIANT CELL ARTERITIS (GCA)